Treatment of sickle-cell disease.
D000755:Anemia, Sickle Cell / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D000758:Anesthesia; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D001769:Blood; D001783:Blood Flow Velocity; D001809:Blood Viscosity; D001831:Body Temperature; D001854:Bone Marrow Cells; D003485:Cyanates / Q000627:therapeutic use; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006451:Hemoglobin, Sickle / Q000032:analysis; D006461:Hemolysis; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006920:Hygiene; D007238:Infarction / Q000209:etiology; D007671:Kidney Concentrating Ability; D007871:Leg Ulcer / Q000209:etiology; D008297:Male; D008428:Maternal Mortality; D008961:Models, Structural; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000628:therapy; D013924:Thrombophlebitis / Q000209:etiology; D014508:Urea / Q000627:therapeutic use
D000925:Anticoagulants; D001639:Bicarbonates; D003485:Cyanates; D006451:Hemoglobin, Sickle; D014508:Urea; D005492:Folic Acid; D001241:Aspirin